Bill is a leader with a demonstrated history of taking companies from concept to exit. Bill currently is the board chair of Genezen, a biotech contract manufacturer of viral vectors, cell manufacturing, and testing services. He founded the company fourteen years ago and grew it from his one-person operation to over 60 employees with outside investment of $45 million. Prior to starting Genezen, Bill was President and CEO at Rimedion, a gene therapy company developing treatments for rare genetic disorders. He currently serves on the board of Cellular Engineering Technologies, a stem cell services company. He has spent the last 35 years working in the consumer products, pharma, and biotech sectors.Bill has an undergraduate double majored in Microbiology and Biochemistry and holds an MBA from the University of Texas with a concentration in Accounting. Additionally, he participated in a two-year executive development program with Philip Morris. Over the last 24 years, he has worked with startups in various areas including software, medical devices, biotechnology, retail services, and real estate investment. He has held roles as CEO, President, founder, board member, advisor, and consultant.